STOCK TITAN

Lifeward Ltd. Ordinary Shares - LFWD STOCK NEWS

Welcome to our dedicated page for Lifeward Ltd. Ordinary Shares news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward Ltd. Ordinary Shares stock.

Lifeward™, formerly known as ReWalk Robotics Ltd, is a pioneering medical device company dedicated to transforming the lives of individuals with physical limitations and disabilities. Founded in 2001, Lifeward designs, develops, and commercializes innovative solutions that span the continuum of care in physical rehabilitation and recovery. The company's mission is to relentlessly drive innovation, delivering functional and health benefits in clinical settings as well as in the home and community.

Headquartered in the United States, with additional operations in Israel and Germany, Lifeward's product portfolio includes the ReWalk Personal Exoskeleton, ReWalk Rehabilitation Exoskeleton, AlterG Anti-Gravity systems, ReStore Exo-Suit, and MyoCycle FES systems. These devices empower individuals to achieve their goals through improved mobility and health outcomes.

Lifeward has garnered significant recognition for its life-changing technology, particularly the ReWalk Exoskeleton, which has been crucial for individuals with spinal cord injuries. The company's efforts have been acknowledged by the Centers for Medicare & Medicaid Services (CMS), which has made strides in establishing a reimbursement pathway for the ReWalk Personal Exoskeleton. This development is a significant step toward making this revolutionary technology accessible to more people.

In recent news, Lifeward has unveiled its new branding and expanded its portfolio with the inclusion of AlterG Anti-Gravity systems. The rebranding reflects the company's broader vision and commitment to elevating the standard of care for individuals facing physical limitations. CEO Larry Jasinski stated that the transformation to Lifeward symbolizes their goal to be the driving force in overcoming physical disabilities.

Lifeward operates through markets in the United States and Europe, with additional sales in Asia, the Middle East, and South America. The company's financial health remains robust, as evidenced by their latest financial results and continuous efforts to innovate and expand their market presence. Lifeward's commitment to excellence is further highlighted by partnerships with healthcare providers and legislative efforts to enhance access to their technologies for veterans and other individuals in need.

For more information about Lifeward's mission and product offerings, visit GoLifeward.com.

Rhea-AI Summary

Lifeward, formerly known as ReWalk Robotics (NASDAQ: LFWD), will be presenting at the Sidoti Small Cap Conference on June 12-13, 2024. CEO Larry Jasinski and CFO Mike Lawless will lead the presentation and conduct one-on-one meetings with investors. The presentation will start at 9:15 AM EDT on June 12 and will be accessible live. Lifeward will also host virtual one-on-one sessions with investors during the conference. Registration for the presentation and individual meetings is free and open to all interested investors through the Sidoti website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
conferences
-
Rhea-AI Summary

Lifeward (NASDAQ: LFWD) reported a Q1 2024 revenue increase of 340% year-over-year to $5.3 million, driven by a new Medicare payment for ReWalk Personal Exoskeletons, resulting in 14 approved claims. However, the gross margin declined from 46.4% to 26.4%, mainly due to low sales volume of AlterG products. Operating expenses rose to $7.9 million, leading to an operating loss of $6.5 million and a net loss of $6.3 million, or $0.73 per share. Liquidity stood at $20.7 million in cash with no debt. The company anticipates 2024 revenue between $28 to $32 million, expecting better performance in Q2 due to enhanced Medicare reimbursements and a more effective sales team.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
-
Rhea-AI Summary

Lifeward, a global market leader in rehabilitation solutions, will report its first quarter 2024 financial results on May 15, 2024. The company aims to revolutionize rehabilitation, recovery, and life's pursuits for those with physical limitations or disabilities. The earnings call will be hosted by CEO Larry Jasinski and CFO Michael Lawless.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.47%
Tags
conferences earnings
Rhea-AI Summary
Lifeward appoints Mike Swinford, an experienced healthcare and rehabilitation technology professional, to its Board of Directors. Swinford brings over 30 years of expertise in commercialization and new business development, having served as the CEO of Numotion and in various roles at GE Healthcare. His appointment aims to strengthen Lifeward's leadership in delivering life-changing solutions for individuals with physical limitations or disabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
management
-
Rhea-AI Summary
ReWalk Robotics (Nasdaq: LFWD) announces finalized Medicare reimbursement pathway for personal exoskeletons, expanding access for eligible beneficiaries. CMS sets final lump-sum purchase fee schedule amount, providing clarity for physicians and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
none
-
Rhea-AI Summary
ReWalk Robotics (LFWD) collaborates with CMS to determine final payment rate for ReWalk Exoskeletons. CMS to update fee schedule after April 1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
Rhea-AI Summary
ReWalk Robotics (DBA Lifeward™), a global leader in assistive technologies, applauds the introduction of a Senate companion bill to H.R. 6373, the VA Spinal Trauma Access to New Devices (STAND) Act. The legislation aims to provide annual examinations and assessments for assistive technologies, including Personal Exoskeletons, for Veterans with Spinal Cord Injury, increasing access to life-changing solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.29%
Tags
none
-
News
Rhea-AI Summary
ReWalk Robotics Ltd. (LFWD) announces a 1-for-7 reverse split to meet Nasdaq listing standards. The split aims to increase share price above $1.00 while reducing outstanding shares. The split will apply to warrants and stock options, with issued shares decreasing from 60.1 million to 8.6 million post-split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
-
Rhea-AI Summary
Two recent research publications highlight the effectiveness of the ReStore Exo-Suit in improving walking ability for post-stroke patients. The studies show significant improvements in walking speed and distance, emphasizing the clinical value of Lifeward's technology for rehabilitation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
none
Rhea-AI Summary
ReWalk Robotics Ltd. (Nasdaq: LFWD) announced a deferral in pricing decision for personal exoskeletons by CMS, with payment determination on a case-by-case basis until finalized. Lifeward has provided 35 exoskeletons to Medicare beneficiaries to support demand.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none

FAQ

What is the current stock price of Lifeward Ltd. Ordinary Shares (LFWD)?

The current stock price of Lifeward Ltd. Ordinary Shares (LFWD) is $1.48 as of January 28, 2025.

What is the market cap of Lifeward Ltd. Ordinary Shares (LFWD)?

The market cap of Lifeward Ltd. Ordinary Shares (LFWD) is approximately 15.5M.

What is Lifeward?

Lifeward, formerly known as ReWalk Robotics Ltd, is a medical device company that designs, develops, and commercializes innovative solutions for physical rehabilitation and recovery.

What products does Lifeward offer?

Lifeward's product portfolio includes the ReWalk Personal Exoskeleton, ReWalk Rehabilitation Exoskeleton, AlterG Anti-Gravity systems, ReStore Exo-Suit, and MyoCycle FES systems.

Where does Lifeward operate?

Lifeward operates primarily in the United States and Europe, with additional sales in Asia, the Middle East, and South America.

What recent achievements has Lifeward made?

Lifeward recently rebranded from ReWalk Robotics Ltd and expanded its portfolio with the AlterG Anti-Gravity systems, reflecting a broader vision for physical rehabilitation and recovery.

How does the ReWalk Personal Exoskeleton benefit users?

The ReWalk Personal Exoskeleton aids individuals with spinal cord injuries by improving their mobility and providing significant health benefits.

What is the CMS reimbursement pathway for the ReWalk Personal Exoskeleton?

CMS has made strides in establishing a reimbursement pathway for the ReWalk Personal Exoskeleton, allowing Medicare patients access to this technology with an established payment rate.

Who founded Lifeward and when?

Lifeward was founded in 2001 and has since grown to become a leader in innovative solutions for physical rehabilitation and recovery.

What is Lifeward's mission?

Lifeward's mission is to relentlessly drive innovation to improve the lives of individuals with physical limitations or disabilities, enabling them to do what they love.

How can I learn more about Lifeward's products and mission?

For more information about Lifeward's products and mission, visit their official website at www.GoLifeward.com.

Who should I contact for media or investor relations at Lifeward?

For media inquiries, contact LifeSci Communications at media@golifeward.com. For investor relations, contact Mike Lawless, Chief Financial Officer, at ir@golifeward.com.
Lifeward Ltd. Ordinary Shares

Nasdaq:LFWD

LFWD Rankings

LFWD Stock Data

15.52M
10.25M
2.77%
21.64%
1.53%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
MARLBOROUGH